Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

151.83
+2.331.56%
Post-market: 151.830.00000.00%16:17 EDT
Volume:1.18M
Turnover:178.28M
Market Cap:15.49B
PE:22.25
High:152.07
Open:151.14
Low:149.71
Close:149.50
52wk High:186.12
52wk Low:122.14
Shares:102.00M
Float Shares:100.00M
Volume Ratio:1.20
T/O Rate:1.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.82
EPS(LYR):4.67
ROE:22.09%
ROA:11.70%
PB:4.19
PE(LYR):32.51

Loading ...

Neurocrine Biosciences Announces Key Leadership Hiring, Promotions

THOMSON REUTERS
·
Jul 24

Neurocrine Appoints Samir Siddhanti as Chief Business Officer

Reuters
·
Jul 22

Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer

THOMSON REUTERS
·
Jul 22

Neurocrine is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 21

Neurocrine Biosciences (NBIX) Stock Looks Reasonable At Today’s Price

Simply Wall St.
·
Jul 20

Neurocrine Biosciences, Inc. : Wells Fargo Raises Target Price to $200 from $175

THOMSON REUTERS
·
Jul 17

Wells Fargo Remains a Buy on Neurocrine (NBIX)

TIPRANKS
·
Jul 17

Neurocrine Biosciences Chief Legal Officer Darin Lippoldt Reports Common Stock Sale Worth $1.8 Million

Reuters
·
Jul 14

Neurocrine is Maintained at Buy by Truist Securities

Dow Jones
·
Jul 14

Neurocrine price target raised to $200 from $155 at Truist

TIPRANKS
·
Jul 13

Analysts Are Bullish on These Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Neurocrine (NBIX)

TIPRANKS
·
Jul 13

Wedbush Lifts Price Target on Neurocrine Biosciences to $185 From $176, Keeps Outperform Rating

MT Newswires Live
·
Jul 13

Krystal Biotech Stock And 2 Biotech Names With Pipeline Catalysts

Simply Wall St.
·
Jul 13

Neurocrine Biosciences (NBIX) Posts Strong Q1 Results, Is More Upside Still Left?

Simply Wall St.
·
Jul 11

Did Neurocrine’s (NBIX) CRENESSITY Push Into Infants Just Recast Its Rare-Disease Strategy?

Simply Wall St.
·
Jul 10

Neurocrine Chief Regulatory Officer Ingrid Delaet Disposes of 14,571 Common Shares Worth $2.6 Million

Reuters
·
Jul 10

Neurocrine Biosciences Schedules Q2 Earnings Conference Call and Webcast

Reuters
·
Jul 10

Ovid Therapeutics Names Kevin Norrett Chief Business Officer

Reuters
·
Jul 08

RBC Capital Adjusts Neurocrine Biosciences Price Target to $195 From $183, Maintains Outperform Rating

MT Newswires Live
·
Jul 07

Neurocrine Begins Phase 2 Trial of Crinecerfont in Children Under 4 Years With Classic CAH Genetic Condition

MT Newswires Live
·
Jul 02